Endonovo Therapeutics, Inc. (ENDV)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 6.92 Million USD | 121.55% |
| 2022 | -32.13 Million USD | -694.24% |
| 2021 | -4.04 Million USD | -99.67% |
| 2020 | -2.02 Million USD | 91.34% |
| 2019 | -23.4 Million USD | -263.66% |
| 2018 | -6.43 Million USD | 40.46% |
| 2017 | -10.81 Million USD | -103.36% |
| 2016 | -5.31 Million USD | -4.66% |
| 2015 | -5.07 Million USD | -429.35% |
| 2014 | -959.49 Thousand USD | 66.83% |
| 2013 | -2.89 Million USD | -51.1% |
| 2012 | -1.91 Million USD | -1934.85% |
| 2011 | -94.08 Thousand USD | -35.57% |
| 2010 | -69.4 Thousand USD | 78.97% |
| 2009 | -330 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -721.29 Thousand USD | -1.68% |
| 2024 Q1 | -709.37 Thousand USD | 55.76% |
| 2023 Q4 | -1.6 Million USD | -109.27% |
| 2023 Q1 | 14.68 Million USD | 244.34% |
| 2023 Q3 | -766.17 Thousand USD | -137.13% |
| 2023 Q2 | 2.06 Million USD | -85.94% |
| 2023 FY | 6.92 Million USD | 121.55% |
| 2022 Q3 | -709.94 Thousand USD | 78.18% |
| 2022 Q1 | -4.34 Million USD | -281.14% |
| 2022 FY | -32.13 Million USD | -694.24% |
| 2022 Q4 | -10.17 Million USD | -1332.61% |
| 2022 Q2 | -3.25 Million USD | 25.05% |
| 2021 Q2 | -1.29 Million USD | 51.63% |
| 2021 FY | -4.04 Million USD | -99.67% |
| 2021 Q1 | -2.68 Million USD | -32.04% |
| 2021 Q4 | 2.39 Million USD | 257.27% |
| 2021 Q3 | -1.52 Million USD | -17.51% |
| 2020 Q1 | 4.33 Million USD | 176.59% |
| 2020 FY | -2.02 Million USD | 91.34% |
| 2020 Q2 | -1.63 Million USD | -137.68% |
| 2020 Q3 | -1.06 Million USD | 34.6% |
| 2020 Q4 | -2.03 Million USD | -89.92% |
| 2019 Q4 | -5.66 Million USD | -302.83% |
| 2019 FY | -23.4 Million USD | -263.66% |
| 2019 Q1 | -2.4 Million USD | -274.1% |
| 2019 Q2 | -7.83 Million USD | -225.72% |
| 2019 Q3 | -1.4 Million USD | 82.06% |
| 2018 Q3 | -5.94 Million USD | -375.54% |
| 2018 Q1 | -618.91 Thousand USD | -134.99% |
| 2018 FY | -6.43 Million USD | 40.46% |
| 2018 Q4 | 1.38 Million USD | 123.24% |
| 2018 Q2 | -1.25 Million USD | -102.1% |
| 2017 Q2 | 1.85 Million USD | 123.93% |
| 2017 Q1 | -7.76 Million USD | -949.56% |
| 2017 FY | -10.81 Million USD | -103.36% |
| 2017 Q4 | 1.76 Million USD | 126.51% |
| 2017 Q3 | -6.67 Million USD | -459.1% |
| 2016 Q3 | -2.21 Million USD | -52.65% |
| 2016 Q1 | -903.46 Thousand USD | 68.19% |
| 2016 Q4 | -739.83 Thousand USD | 66.66% |
| 2016 FY | -5.31 Million USD | -4.66% |
| 2016 Q2 | -1.45 Million USD | -60.89% |
| 2015 Q3 | -1.28 Million USD | -129.69% |
| 2015 FY | -5.07 Million USD | -429.35% |
| 2015 Q4 | -2.84 Million USD | -121.73% |
| 2015 Q2 | -557.72 Thousand USD | -16.15% |
| 2015 Q1 | -480.15 Thousand USD | -115.39% |
| 2014 Q2 | -202.68 Thousand USD | 67.75% |
| 2014 FY | -959.49 Thousand USD | 66.83% |
| 2014 Q1 | -628.51 Thousand USD | 6.81% |
| 2014 Q4 | -222.92 Thousand USD | -335.57% |
| 2014 Q3 | 94.63 Thousand USD | 146.69% |
| 2013 Q4 | -674.45 Thousand USD | -49.08% |
| 2013 FY | -2.89 Million USD | -51.1% |
| 2013 Q1 | -1.12 Million USD | -122.85% |
| 2013 Q2 | -639.99 Thousand USD | 43.16% |
| 2013 Q3 | -452.39 Thousand USD | 29.31% |
| 2012 Q4 | -505.26 Thousand USD | -28.6% |
| 2012 FY | -1.91 Million USD | -1934.85% |
| 2012 Q1 | -430.78 Thousand USD | -2053.92% |
| 2012 Q2 | -430.6 Thousand USD | 0.04% |
| 2012 Q3 | -392.89 Thousand USD | 8.76% |
| 2011 Q3 | -20 Thousand USD | 0.0% |
| 2011 FY | -94.08 Thousand USD | -35.57% |
| 2011 Q4 | -20 Thousand USD | 0.0% |
| 2010 FY | -69.4 Thousand USD | 78.97% |
| 2010 Q4 | -20 Thousand USD | 0.0% |
| 2010 Q3 | -20 Thousand USD | 0.0% |
| 2009 FY | -330 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 52.97 Million USD | 86.93% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 1194.958% |
| Nascent Biotech, Inc. | -2.08 Million USD | 431.688% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 1766.653% |
| Qrons Inc. | -789.34 Thousand USD | 977.256% |
| Rebus Holdings, Inc. | -1.02 Million USD | 778.882% |
| Skye Bioscience, Inc. | -37.64 Million USD | 118.395% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 89.369% |
| Adynxx, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 618.529% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 111.062% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 143.629% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 199.166% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 109.237% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 205.299% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 2632.752% |
| SQZ Biotechnologies Company | -79.46 Million USD | 108.714% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 339.407% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 480.362% |
| Mesoblast Limited | -87.95 Million USD | 107.873% |
| Marizyme, Inc. | -65.34 Million USD | 110.597% |
| Genus plc | 7.9 Million USD | 12.347% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 163.577% |
| Pharming Group N.V. | -10.54 Million USD | 165.648% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 419.133% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 286.635% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 178.297% |
| ContraFect Corporation | -65.15 Million USD | 110.628% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 241.721% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 500.855% |
| IMV Inc. | -36.48 Million USD | 118.979% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 185.916% |
| MultiCell Technologies, Inc. | -380.07 USD | 1822025.961% |
| ONE Bio Corp. | 8.67 Million USD | 20.192% |
| Accustem Sciences Inc. | -3.74 Million USD | 284.832% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 113.396% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 646.477% |
| Q BioMed Inc. | -2.05 Million USD | 437.441% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 285.497% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 390.843% |
| Biomind Labs Inc. | -1.21 Million USD | 670.245% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 111.594% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 323.247% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 187.619% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 455.244% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 46337.941% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 219.035% |
| GB Sciences, Inc. | -1.36 Million USD | 608.534% |
| Alpha Cognition Inc. | -13.77 Million USD | 150.278% |
| HST Global, Inc. | -146.21 Thousand USD | 4836.06% |
| CSL Limited | 2.64 Billion USD | 99.738% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 494.615% |
| Halberd Corporation | -79.67 Thousand USD | 8790.941% |
| Enzolytics Inc. | -2.17 Million USD | 418.104% |
| Agentix Corp. | -1.37 Million USD | 603.896% |
| Resverlogix Corp. | -3.61 Million USD | 291.817% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 318.343% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -295.05 Million USD | 102.347% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -6965.912% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 274.292% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 328.826% |
| AVAX Technologies, Inc. | -6.41 Million USD | 207.967% |
| Zenith Capital Corp. | -10.59 Million USD | 165.351% |
| Genscript Biotech Corporation | -95.47 Million USD | 107.253% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 29893.452% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 267.021% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 11556.857% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 445.346% |
| Kadimastem Ltd | -3.3 Million USD | 309.367% |
| Helix BioMedix, Inc. | -1.05 Million USD | 755.703% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 281.32% |
| BioStem Technologies, Inc. | -8.48 Million USD | 181.629% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 1668.89% |
| LadRx Corporation | 400.44 Thousand USD | -1629.233% |
| Cell Source, Inc. | -5.32 Million USD | 230.132% |
| Regen BioPharma, Inc. | 1.02 Million USD | -576.555% |
| Regen BioPharma, Inc. | 1.02 Million USD | -576.555% |
| NovAccess Global Inc. | -4.76 Million USD | 245.194% |
| Affymax, Inc. | -14.42 Million USD | 148.007% |
| Itoco Inc. | -1.86 Million USD | 470.498% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 255.87% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 514.895% |
| Mobile Lads Corp. | -2.26 Million USD | 405.952% |
| CytoDyn Inc. | -49.84 Million USD | 113.893% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 8861.649% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 3135.412% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 835.463% |
| SYBLEU INC | -180.3 Thousand USD | 3940.51% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 529.369% |
| International Stem Cell Corporation | -131 Thousand USD | 5385.95% |
| Bioxytran, Inc. | -4.28 Million USD | 261.79% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 12859.054% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 373.673% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 114.405% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 427.559% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 986.76% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 318.579% |
| Neutra Corp. | -233.46 Thousand USD | 3066.009% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 134.126% |
| PureTech Health plc | -65.69 Million USD | 110.54% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 132.561% |
| IXICO plc | -1.17 Million USD | 687.826% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 169.755% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 112.121% |
| CSL Limited | 2.64 Billion USD | 99.738% |
| Cellectis S.A. | -103.17 Million USD | 106.712% |